Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
Theravance Biopharma (NASDAQ: TBPH) will present two rapid-fire analyses of YUPELRI (revefenacin) at the 2025 CHEST Annual Meeting in Chicago, Oct 19–22, 2025.
A retrospective claims study reported that patients adherent to YUPELRI after COPD hospital discharge had significantly fewer and less severe exacerbations and significantly lower healthcare costs versus non-adherent patients. Post-hoc analyses of a 52-week Phase 3 safety study found lower incidence of moderate-to-severe exacerbations and overall less severe exacerbations versus tiotropium. Presentation details list presenters, titles, and Oct 21, 2025 times.
Theravance Biopharma (NASDAQ: TBPH) presenterà due analisi rapide di YUPELRI (revefenacin) al CHEST Annual Meeting 2025 a Chicago, dal 19 al 22 ottobre 2025.
Uno studio retrospettivo basato sui dati di reclami ha riportato che i pazienti aderenti a YUPELRI dopo la dimissione dall'ospedale per BPCO hanno meno esacerbazioni e meno gravi e costi sanitari significativamente inferiori rispetto ai pazienti non aderenti. Le analisi post-hoc di uno studio di sicurezza di fase 3 della durata di 52 settimane hanno rilevato una minore incidenza di esacerbazioni da moderate a gravi e, in generale, meno esacerbazioni gravi rispetto al tiotropio. I dettagli della presentazione elencano relatori, titoli e orari del 21 ottobre 2025.
Theravance Biopharma (NASDAQ: TBPH) presentará dos análisis rápidos de YUPELRI (revefenacin) en la Reunión Anual 2025 de CHEST en Chicago, del 19 al 22 de octubre de 2025.
Un estudio retrospectivo basado en datos de reclamaciones informó que los pacientes adherentes a YUPELRI tras el alta por EPOC tenían muchas menos y menos graves exacerbaciones y costos de atención médica significativamente menores en comparación con los pacientes no adherentes. Análisis post-hoc de un ensayo de seguridad de fase 3 de 52 semanas encontraron una menor incidencia de exacerbaciones moderadas a graves y, en general, menos exacerbaciones graves en comparación con tiotropio. Los detalles de la presentación enumeran ponentes, cargos y horarios del 21 de octubre de 2025.
Theravance Biopharma (NASDAQ: TBPH)는 YUPELRI (revefenacin)에 대한 두 가지 빠른 분석을 2025 CHEST 연례 회의에서 시카고에서 발표할 예정입니다. 일정: 2025년 10월 19–22일.
회고적 청구 데이터 연구에 따르면 COPD로 병원에서 퇴원한 후 YUPELRI를 지속한 환자들은 악화가 더 적고 더 경미하며 비용도 현저히 낮았다고 보고되었습니다. 52주 기간의 제3상 안전성 연구에 대한 사후 분석은 중등도에서 중증 악화의 발생률 감소와 tiotropio에 비해 전반적으로 악화가 덜 발생한다는 결과를 보였습니다. 발표 세부 정보에는 발표자, 직함, 2025년 10월 21일의 시간들이 나와 있습니다.
Theravance Biopharma (NASDAQ: TBPH) présentera deux analyses rapides de YUPELRI (revefenacin) lors de la CHEST Annual Meeting 2025 à Chicago, du 19 au 22 octobre 2025.
Une étude rétrospective basée sur les données de réclamations a montré que les patients adhérents à YUPELRI après une sortie d’hôpital pour BPCO avaient moins d’exacerbations et moins graves et des coûts de soins de santé significativamente inférieurs par rapport aux patients non adhérents. Des analyses post-hoc d’une étude de sécurité de phase 3 de 52 semaines ont trouvé une incidence plus faible d’exacerbations modérées à sévères et, globalement, moins d’exacerbations graves par rapport au tiotropium. Les détails de la présentation listent les intervenants, les titres et les créneaux du 21 octobre 2025.
Theravance Biopharma (NASDAQ: TBPH) wird zwei kurze Analysen zu YUPELRI (revefenacin) auf dem CHEST Annual Meeting 2025 in Chicago vom 19. bis 22. Oktober 2025 vorstellen.
Eine retrospektive Claims-Studie zeigte, dass Patienten, die nach einer COPD-Krankenhausentlassung YUPELRI fortführten, wesentlich weniger und weniger schwerwiegende Exazerbationen und deutlich geringere Gesundheitskosten hatten als nicht-adherente Patienten. Post-hoc-Analysen einer 52-wöchigen Phase-3-Sicherheitsstudie ergaben eine geringere Inzidenz von moderaten bis schweren Exazerbationen und insgesamt weniger schwere Exazerbationen im Vergleich zu Tiotropium. Die Präsentationsdetails führen Referenten, Titel und Zeiten vom 21. Oktober 2025 auf.
Theravance Biopharma (NASDAQ: TBPH) ستقدم تحليلين سريعَيْن لـ YUPELRI (revefenacin) في اجتماع CHEST السنوي لعام 2025 في شيكاجو، من 19 إلى 22 أكتوبر 2025.
أفادت دراسة استعادية قائمة على المطالبات بأن المرضى الذين امتثلوا لـ YUPELRI بعد خروجهم من المستشفى نتيجة COPD كان لديهم مضاعفات أقل وأقل حدة و تكاليف رعاية صحية أقل بشكل ملحوظ مقارنةً بالمرضى غير الملتزمين. أظهرت التحليلات اللاحقة لدراسة أمان من المرحلة الثالثة لمدة 52 أسبوعاً انخفاضاً في حدوث تفاقمات متوسطة إلى شديدة وبشكل عام تفاقمات أقل حدة مقارنةً بالتيوتروبيوم. تفاصيل العرض تذكر مقدّمين، عناوين، وأوقات يوم 21 أكتوبر 2025.
Theravance Biopharma (NASDAQ: TBPH) 将在 2025 年 CHEST 年会于芝加哥于 2025 年 10 月 19–22 日举行时，展示两项关于 YUPELRI (revefenacin) 的快速分析。
一项基于索赔数据的回顾性研究显示，在 COPD 出院后坚持使用 YUPELRI 的患者相比不坚持者，发作次数更少且更轻，因此造成的医疗成本显著较低。对一项 52 周的 III 期安全性研究的事后分析发现，与tiotropium相比，中到重度发作的发生率降低，整体发作也较少。演讲详情列出了发言人、头衔和 2025 年 10 月 21 日的时间。
- None.
- None.
- A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent to YUPELRI experienced significantly fewer, and less severe, exacerbations and had significantly lower healthcare costs than non-adherent patients
- Post-hoc analyses of a Phase 3 safety study showed that patients taking YUPELRI had significantly lower incidence of moderate-to-severe acute exacerbations, and overall, less severe exacerbations, than patients taking tiotropium
"We are pleased to share new analyses on YUPELRI at the upcoming CHEST Annual Meeting. The findings of the retrospective database analysis of claims data evaluating exacerbations in the 3 months following hospital discharge demonstrates that adherent patients to YUPELRI had significantly fewer exacerbations, and particularly less severe ones, compared to non-adherent patients," commented Antonio Anzueto, M.D., Professor of Medicine, Pulmonary/Critical Section, University of
Details on the presentations are as follows:
Title: Exacerbation Rates in COPD Patients: A Retrospective Analysis of the Nebulized Once Daily Long-Acting Muscarinic Antagonist Revefenacin in a 52-Week Safety Study
Presenter: Edmund J Moran, Ph.D., Theravance Biopharma
Date and time: October 21, 2025; 10:56 – 11:00 AM CT; Emerging Trends in COPD
Title: Adherence to Revefenacin Associated with Reductions in Exacerbations and Healthcare Costs Following a COPD-Related Hospitalization
Presenter: Grace Leung, MPH, Zavicus Consulting
Date and time: October 21, 2025; 2:15 – 2:19 PM CT; Current Updates in COPD
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first-in-class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the
YUPELRI® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
About Theravance Biopharma / Viatris Collaboration
Theravance Biopharma and Viatris Inc. and their respective affiliates have established a strategic collaboration to develop and commercialize nebulized revefenacin products for COPD.
Forward-Looking Statements
This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma, Inc. (the "Company") intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company's expectations regarding its future profitability, expenses and uses of cash, the Company's goals, designs, strategies, plans and objectives, future growth of YUPELRI sales, future royalty payments, the ability to provide value to shareholders, the Company's regulatory strategies and timing of clinical studies, possible safety, efficacy or differentiation of our investigational therapy, the status of patent infringement litigation initiated by the Company and its partner against certain generic companies in federal district courts, contingent payments due to the Company from the sale of the Company's TRELEGY ELLIPTA royalty interests to Royalty Pharma, and expectations around the use of OHSA scores as endpoints for clinical trials. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: factors that could increase the Company's cash requirements or expenses beyond its expectations and any factors that could adversely affect its profitability, whether the milestone thresholds can be achieved, delays or difficulties in commencing, enrolling or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's product candidates or product are unsafe, ineffective or not differentiated, risks of decisions from regulatory authorities that are unfavorable to the Company, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop, manufacture and commercialize products, and risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure, the ability of the Company to protect and to enforce its intellectual property rights, volatility and fluctuations in the trading price and volume of the Company's shares, and general economic and market conditions. Other risks affecting the Company are in the Company's Form 10-Q filed with the SEC on August 13, 2025, and other periodic reports filed with the SEC. In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-new-analyses-highlighting-yupelri-revefenacin-outcomes-in-copd-at-the-2025-chest-annual-meeting-302583065.html
SOURCE Theravance Biopharma, Inc.
FAQ
What new YUPELRI (TBPH) findings will be presented at CHEST 2025?
When and where will Theravance Biopharma present YUPELRI data at CHEST 2025 (TBPH)?
What did the retrospective claims analysis report about YUPELRI adherence after hospitalization?
How did YUPELRI perform versus tiotropium in the 52-week Phase 3 post-hoc analysis?
Who are the presenters for the YUPELRI studies at CHEST 2025 (TBPH)?
How long are the YUPELRI presentations at CHEST 2025 and where can investors find them?
